CN105561313B - It reduces 5-HT2BR content and its active substance is inhibited to treat and prevent the application in atherosclerosis product in preparation - Google Patents
It reduces 5-HT2BR content and its active substance is inhibited to treat and prevent the application in atherosclerosis product in preparation Download PDFInfo
- Publication number
- CN105561313B CN105561313B CN201610049371.8A CN201610049371A CN105561313B CN 105561313 B CN105561313 B CN 105561313B CN 201610049371 A CN201610049371 A CN 201610049371A CN 105561313 B CN105561313 B CN 105561313B
- Authority
- CN
- China
- Prior art keywords
- ht2br
- atherosclerosis
- smooth muscle
- content
- artery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
The invention discloses reduce 5-HT2BR content and its active substance is inhibited to treat and prevent the application in atherosclerosis product in preparation.It is demonstrated experimentally that the 5-HT2BR specific antagonists for reducing 5-HT2BR expression can inhibit the migration of smooth muscle cell, the content of smooth muscle cell in atherosclerotic plaque can be reduced, the formation of atherosclerotic plaque can be inhibited；The 5-HT2BR specific agonist for improving 5-HT2BR expression can promote the migration of smooth muscle cell.5-HT2BR and its encoding gene of the invention can be used as the target proteins and target gene for the treatment of and/or prevention of arterial atherosclerotic lesion respectively, it reduces 5-HT2BR expression or inhibits its active substance that can be used to treat and prevent atherosclerosis associated diseases, can also be used to the drug of preparation treatment and/or prevention of arterial atherosis associated diseases.
Description
Technical field
The present invention relates in field of biomedicine reduce 5-HT2BR content and inhibit its active substance preparation treatment and
Application in prevention of arterial atherosis product.
Background technique
Atherosclerosis is to deposit institute at blood vessel (mainly artery) by fat, thrombus, connective tissue and calcium carbonate
Caused by a kind of state being harmful to the human body, it is a kind of high morbidity for endangering human health, high dead, the high great disease to disable
Disease, it is even dead that this disease can cause patient's myocardial infarction, apoplexy.Atherosclerosis is the unknown multifactor complexity of mechanism
Process, causes vascellum tunica interna incrassation, and lipid is enriched with and forms patch.A kind of controversial theory is think blood vessel important at present
Constituent-smooth muscle cell results in the growth of patch, and under damage factor stimulation Phenotypic Change occurs for smooth muscle cell,
And it is migrated from tunicae media vasorum to inner membrance, proliferation；It is partially converted into foam cells and generates extracellular matrix, so as to cause patch shape
At narrow with vessel lumen.
Serotonin (5-HT) is a kind of monoamine neurotransmitter, and 90% 5-HT derives from enterochromaffin cell, regulates and controls intestines
It wriggles.Remaining serotoninergic nerve member from cental system, regulation mood, appetite and sleep.Blood platelet is the storage of 5-HT
Place, when blood platelet encounters grumeleuse, 5-HT is released, and causes vessel retraction, helps blood coagulation.The function of 5-HT is by 5-
HT is receptor-mediated, and 5-HT receptor has 7 families (5-HT1R-5-HT7R), 14 kinds of subtype acceptors.Except 5-HT3R is ligand sun
Outside ion channel, remaining 5-HT receptor is G- G-protein linked receptor (Gprotein-coupled receptor, GPCR).5-
HT2 receptor (5-HT2R) includes 5-HT2A receptor (5-HT2AR), 5-HT2B receptor (serotonin 2B receptor, 5-HT2BR) and 5-
Three kinds of hypotypes of HT2C receptor (5-HT2CR).
Summary of the invention
How the technical problem to be solved by the present invention is to treat and/or prevention of arterial atherosis and Atherosclerosis
Change associated diseases.
In order to solve the above technical problems, present invention firstly provides reduce animal body in 5-HT2BR content substance or/
With the active substance of 5-HT2BR in inhibition animal body in preparation treatment and/or prevention of arterial atherosis product or by artery
Application in the product of atherosis associated diseases.
In above-mentioned application, the substance for reducing 5-HT2BR content in animal body can be 5- in reduction animal body
The substance of HT2BR encoding gene expression, such as by the method for RNA interference or by regulating and controlling adjustable 5-HT2BR encoding gene table
The factor reached reduces the substance that 5-HT2BR encoding gene in arteries is expressed.
In above-mentioned application, 5- in the substance or the inhibition animal body of 5-HT2BR content in the reduction animal body
The active substance of HT2BR can be 5-HT2BR antagonist (such as LY272015 or RS127445).LY272015 concretely Tocris
Bioscience Products, article No. 3077；RS127445 concretely Tocris Bioscience Products, article No.
It is 2993.
In above-mentioned application, the product can be for treatment and/or prevention of arterial atherosis or caused by atherosclerosis
The drug of disease.
In above-mentioned application, the animal body can be the various positions of the animal, such as artery.The artery can be for actively
Arteries and veins, aortic branch, coronary artery, arteria carotis, cerebral artery, the arteria renalis, mesenteric artery, pulmonary artery or artery of extremity.
In above-mentioned application, the atherosclerosis associated diseases can for vascular smooth muscle cells exception or total cholesterol or
The disease of total content of triglyceride caused extremely；The atherosclerosis can abnormal or total gallbladder be solid for vascular smooth muscle cells
The atherosclerosis of alcohol or total content of triglyceride caused extremely.The vascular smooth muscle cells can be the blood vessel extremely
Migration, proliferation and/or the Phenotypic change of smooth muscle cell.The total cholesterol or total content of triglyceride can be total gallbladder in blood plasma
Sterol or total content of triglyceride.The exception of the total cholesterol or total content of triglyceride can be total cholesterol or total in blood plasma
Content of triglyceride increases.
In above-mentioned application, the atherosclerosis associated diseases can be coronary heart disease.
In order to solve the above technical problems, the present invention also provides following any purposes:
H1) 5-HT2BR is active in the substance or the inhibition animal body of 5-HT2BR content in the reduction animal body
Substance in treatment and/or prevention of arterial atherosis or by the application in atherosclerosis associated diseases；
H2) 5-HT2BR is active in the substance or the inhibition animal body of 5-HT2BR content in the reduction animal body
Substance preparation inhibit smooth muscle cell migration product in application；
H3) 5-HT2BR is active in the substance or the inhibition animal body of 5-HT2BR content in the reduction animal body
Substance inhibit smooth muscle cell migration in application；
H4) 5-HT2BR is as target proteins in treatment and/or prevention of arterial atherosis or caused by atherosclerosis
Application in disease；
H5) encoding gene of 5-HT2BR is as target gene in treatment and/or prevention of arterial atherosis or by artery congee
Sample hardens the application in associated diseases；
H6) application of the 5-HT2BR or 5-HT2BR agonist in preparation Atherosclerosis Model.
In such use, the 5-HT2BR agonist can be 5-HT2BR specific agonist BW723C86.BW723C86
Concretely Tocris Bioscience Products, article No. 1059.
In such use, the animal body can be the various positions of the animal, such as artery.The artery can be for actively
Arteries and veins, aortic branch, coronary artery, arteria carotis, cerebral artery, the arteria renalis, mesenteric artery, pulmonary artery or artery of extremity.
In such use, the atherosclerosis associated diseases can for vascular smooth muscle cells exception or total cholesterol or
The disease of total content of triglyceride caused extremely；The atherosclerosis can abnormal or total gallbladder be solid for vascular smooth muscle cells
The atherosclerosis of alcohol or total content of triglyceride caused extremely.The vascular smooth muscle cells can be the blood vessel extremely
Migration, proliferation and/or the Phenotypic change of smooth muscle cell.The total cholesterol or total content of triglyceride can be total gallbladder in blood plasma
Sterol or total content of triglyceride.The exception of the total cholesterol or total content of triglyceride can be total cholesterol or total in blood plasma
Content of triglyceride increases.
In such use, the atherosclerosis associated diseases can be coronary heart disease.
In order to solve the above technical problems, the present invention also provides following X1) or product X2):
X1 the drug of the atherosclerosis or the atherosclerosis associated diseases) is treated and/or prevented, is lived
Property ingredient be it is described reduction animal body in 5-HT2BR content substance or the inhibition animal body in 5-HT2BR it is active
Substance；
X2) for treating and/or preventing the substance of the atherosclerosis or the atherosclerosis associated diseases
X, the substance X are that 5-HT2BR is living in the substance or the inhibition animal body of 5-HT2BR content in the reduction animal body
The substance of property.
In the said goods, the animal body can be the various positions of the animal, such as artery.The artery can be for actively
Arteries and veins, aortic branch, coronary artery, arteria carotis, cerebral artery, the arteria renalis, mesenteric artery, pulmonary artery or artery of extremity.
In the said goods, the atherosclerosis associated diseases can for vascular smooth muscle cells exception or total cholesterol or
The disease of total content of triglyceride caused extremely；The atherosclerosis can abnormal or total gallbladder be solid for vascular smooth muscle cells
The atherosclerosis of alcohol or total content of triglyceride caused extremely.
In the said goods, the vascular smooth muscle cells extremely can for the vascular smooth muscle cells migration, proliferation and/
Or Phenotypic change.The total cholesterol or total content of triglyceride can be total cholesterol or total content of triglyceride in blood plasma.Institute
The exception for stating total cholesterol or total content of triglyceride can increase for total cholesterol in blood plasma or total content of triglyceride.
In the said goods, the atherosclerosis associated diseases can be coronary heart disease.
In the present invention, treatment and/or prevention of arterial atherosis, treatment and/or prevention of arterial atherosis associated diseases
Are as follows: compared with before the treatment or prevention of atherosclerosis associated diseases, atherosclerotic plaque quantity is reduced and/or is moved
The content of total cholesterol and/or total triglycerides decline in the reduction of pulse atherosclerosis patch and/or weight loss and/or blood plasma.
In the present invention, the animal can be mammal, such as people.The atherosclerosis and the atherosclerosis
Associated diseases can be respectively mammal atherosclerosis and atherosclerosis associated diseases, such as the atherosclerosis of people
With atherosclerosis associated diseases.
In the present invention, 5-HT2BR is the 5-HT2BR in vitro animal tissue, in people, mouse or isolated rat tissue
5-HT2BR.The amino acid sequence of the 5-HT2BR of people is sequence 1；The amino acid sequence of the 5-HT2BR of mouse is sequence 2；Rat
5-HT2BR amino acid sequence be sequence 3.
The Phenotypic change of vascular smooth muscle cells in the present invention refers to that vascular smooth muscle cells are higher in differentiation degree
Shrinkage type (differentiated) vascular smooth muscle cells and the lower secreting type of differentiation degree (undifferentiated type or dedifferentiated) blood vessel are flat
Conversion between sliding myocyte.
It is demonstrated experimentally that 5-HT2BR and its encoding gene of the invention can be used as treatment respectively and/or prevention of arterial is athero-
Harden the target proteins and target gene of associated diseases.On RNA and protein level, 5-HT2BR is dynamic in atherosclerosis
Expression in owner's artery is all remarkably higher than non-atherosclerosis animal.Reduce the 5-HT2BR of 5-HT2BR expression
Specific antagonists can inhibit the migration of smooth muscle cell, improve the 5-HT2BR specific agonist of 5-HT2BR expression
It can promote the migration of smooth muscle cell: 1) in processing 24 hours, 5-HT2BR specific agonist treated smooth muscle cell
Migration distance be 221.4 ± 12.8 μm, 1.621 times and 0.922 times of respectively untreated and 5-HT processing；5-HT2BR is special
The migration distance of anisotropic antagonist treated smooth muscle cell is 133.7 ± 10.9 μm, respectively untreated, 5-HT and 5-
0.979 times, 0.557 times and 0.604 times of HT2BR specific agonist processing.2) in processing 24 hours, 5-HT2BR specificity
The migratory activity of agonist treated smooth muscle cell is 96.80 ± 20.63, respectively untreated and 5-HT processing
2.151 times and 0.896 times；The migratory activity of 5-HT2BR specific antagonists treated smooth muscle cell is 52.60 ±
7.467, it is respectively untreated, 1.169 times, 0.487 times and 0.543 times the processing of 5-HT and 5-HT2BR specific agonist.Drop
The 5-HT2BR specific antagonists of low 5-HT2BR expression can inhibit the formation of atherosclerotic plaque: 5-HT2BR
2.758 ± 0.456mm of atherosclerotic plaque area of the test group of animals of specific antagonists RS127445 processing2, show
It writes and is less than control animals；The aorta petal patch face of the test group of animals of 5-HT2BR specific antagonists RS127445 processing
Product is 0.138 ± 0.022mm2, significantly less than control animals.Reduce the 5-HT2BR specific antagonist of 5-HT2BR expression
Agent can reduce total cholesterol level and total content of triglyceride in the weight and animal blood plasma of animal.Reduce 5-HT2BR table
The content of smooth muscle cell in atherosclerotic plaque: 5- can also be reduced up to horizontal 5-HT2BR specific antagonists
Smooth muscle cell accounts for the percentage of plaque area and is in the test group of animals aorta petal patch of HT2BR specific antagonists processing
0.106 ± 0.023%, it is 0.435 times of control-animal, substantially less than control animals.5-HT2BR specific antagonists can be with
Reduce total cholesterol level and total content of triglyceride in animal blood plasma: in processing the 12nd week, total gallbladder in test group of animals blood plasma
Sterol content is 0.78 times of control animals, and total content of triglyceride is the 0.61 of control animals in test group of animals blood plasma
Times.
It is demonstrated experimentally that 5-HT2BR and its encoding gene of the invention can be used as treatment respectively and/or prevention of arterial is athero-
Harden the target proteins and target gene of associated diseases.The substance for reducing 5-HT2BR expression can be used to treat and/or in advance
Anti- atherosclerosis associated diseases can also be used to the drug of preparation treatment and/or prevention of arterial atherosis associated diseases.
Detailed description of the invention
Fig. 1 is the oil red O stain result that ApoE-/- mouse feeds different food aortas posterior from C57BL/6J mouse.Its
In, A-F figure indicates patch oil red O stain (explanation after ApoE-/- mouse western diet (western diet, WD) nursing 12 weeks
Atherosclerosis animal model is successfully established).
Fig. 2 is the expression of the 5-HT2BR in each group mouse aorta.Wherein, A is each group mouse on rna level
The expression of 5-HT2BR in aorta, B are the expression feelings of the 5-HT2BR in protein level each group mouse aorta
Condition；" * " indicates that difference reaches the level of signifiance.
Fig. 3 is the result that each group mouse aorta carries out immunohistochemical staining with 5-HT2BR antibody.Wherein, A ApoE
WD (western diet, western diet) organizes the immunohistochemical staining of mouse aorta (have plaque site) as a result, lower-left in A
Figure is the partial enlarged view of coloration result；B be ApoE WD (western diet, western diet) organize mouse aorta (without
Plaque site) immunohistochemical staining as a result, lower-left figure is the partial enlarged view of coloration result in B；C is C57 mouse aorta
Immunohistochemical staining is as a result, lower-left figure is the partial enlarged view of coloration result in C；D is negative control.
Fig. 4 is the immunofluorescence dyeing result of mouse aorta.Wherein, 5-HT2BR indicates ApoE WD group mouse aorta
The immunofluorescence dyeing result of 5-HT2BR antibody；SMA indicates the immunofluorescence dye of ApoE WD group mouse aorta α-SMA antibody
Color result；DAPI indicates ApoE WD group mouse aorta nuclear targeting result；Merge indicates 5-HT2BR, SMA and DAPI's
Superposition；NC indicates negtive control (negative control).
Fig. 5 is the cell scratch experiment result of different disposal smooth muscle cell migration.Wherein, A is different disposal smooth muscle
Cell migration situation, B are the migration distance of different disposal smooth muscle cell；" * " indicates that difference reaches the level of signifiance.
Fig. 6 is the trans-well experimental result of different disposal smooth muscle cell migration.Wherein, A is that different disposal is smooth
Myocyte's migration situation, B are the migratory activity of different disposal smooth muscle cell；" * " indicates that difference reaches the level of signifiance.
Fig. 7 is influence of the RS127445 to Atherosclerosis Model atherosclerotic plaque in mice.Wherein, A is
The Aorta atheromatous plague of mouse after RS127445 processing；B is the atherosclerosis of aorta of mouse after RS127445 processing
The specific measured value of patch；C is the aorta petal atherosclerotic plaque of mouse after RS127445 processing；D is RS127445
The specific measured value of the aorta petal atherosclerotic plaque of mouse after processing.RS127445 indicates experimental group, velhicle
Indicate control group." * " indicates that difference reaches the level of signifiance.
Fig. 8 is RS127445 to total cholesterol level in Atherosclerosis Model mouse weight and blood plasma and total glycerol
The influence of three ester contents.Wherein, A is influence of the RS127445 to weight, and B is RS127445 to total cholesterol level in blood plasma
It influences, C is influence of the RS127445 to content of triglyceride total in blood plasma.RS127445 indicates experimental group, and velhicle is indicated
Control group." * " indicates that difference reaches the level of signifiance.
Fig. 9 is influence of the RS127445 to Atherosclerosis Model mouse smooth muscle cell.Wherein, A is immunofluorescence
Coloration result, lumen indicate that aortic blood lumen, RS127445 indicate experimental group, and velhicle indicates control group；B is smooth
Myocyte accounts for the percentage of plaque area, and RS indicates experimental group, and V indicates that control group, " * " indicate that difference reaches the level of signifiance.
The immunofluorescence dyeing result of SMA expression α-SMA antibody；DAPI indicates nuclear targeting result；Merge indicates SMA and DAPI
Superposition；NC indicates negtive control (negative control).
Figure 10 is influence of the RS127445 to 5-HT2BR expression in Atherosclerosis Model mouse.Wherein, A is
The expression of 5-HT2BR on rna level in aorta；B is using western-blot to 5-HT2BR expression
Testing result；C is using immunohistochemical staining to the testing result of 5-HT2BR expression, and C1 is the part of Velhicle figure
Enlarged drawing, C2 are the partial enlarged view of RS127445 figure.RS127445 indicates experimental group, and Velhicle indicates control group, " * "
Indicate that difference reaches the level of signifiance.
Specific embodiment
The present invention is further described in detail With reference to embodiment, and the embodiment provided is only for explaining
The bright present invention, the range being not intended to be limiting of the invention.
Experimental method in following embodiments is unless otherwise specified conventional method.
The materials, reagents and the like used in the following examples is commercially available unless otherwise specified.
ApoE-/- mouse in following embodiments is Jackson Lab Products, article No. 002052；Following implementations
C57BL/6J mouse in example is Jackson Lab Products, article No. 000664.
Embodiment 1, the 5-HT2BR high expression in atherosclerosis mouse aorta
1, the foundation of Atherosclerosis Model
The male ApoE- of 20 8 week old/- mouse is randomly divided into two groups, and respectively ApoE CD (chow diet, normally
Diet) group and ApoE WD (western diet, western diet) group, every group 10；By the male C57BL/6J of 20 8 week old
Mouse is randomly divided into two groups, respectively C57CD group and C57WD group, and every group 10.Respectively in ApoE CD group and C57CD group
Every mouse is normally fed；High fat diet is carried out to every mouse in ApoE WD group and C57WD group respectively, feeds food
Object is western diet (western diet, Research Diet company, D12079B).
The aorta of each group mouse is taken to carry out oil red O stain respectively after feeding 12 weeks respectively, the results show that ApoE WD group
Patch (Fig. 1) is formed in rat aorta blood vessel, shows to be successfully established Atherosclerosis Model.
2, the expression of 5-HT2BR detects in Atherosclerosis Model
After four groups of mouse different diets 12 weeks of step 1, the 5- in aorta is detected on rna level
The expression (A in Fig. 2) of HT2BR, primer are GGAGAAAAGGCTGCAGTACG and ATAACCAGGCAGGACACAGG, internal reference
For β-actin, the primer of internal reference is ATCGTGGGCCGCCCTAGGCACC and CTCTTTAATGTCACGCACGATTTC.As a result it shows
Show, on rna level, the 5-HT2BR in C57CD group and C57WD group mouse aorta expresses basic indifference, ApoE CD group
With the high expression of the 5-HT2BR in ApoE WD group mouse aorta, it is significantly higher than respectively in C57CD group mouse aorta
5-HT2BR expression.
After four groups of mouse different diets 12 weeks of step 1, using western-blot on protein level
Detect aorta in 5-HT2BR expression (B in Fig. 2), primary antibody be 5-HT2BR antibody (BDPharmingen,
556334,5-HT2BR antibody can identify 5-HT2BR shown in sequence 2), internal reference is β-actin, and the antibody of internal reference is
(Santa Cruz, sc-47778).The results show that on protein level, in C57CD group and C57WD group mouse aorta
5-HT2BR expression is lower, and the high expression of the 5-HT2BR in ApoE CD group and ApoE WD group mouse aorta.
After four groups of mouse different diets 12 weeks of step 1, aorta is taken to carry out vessel cross-sections frozen section,
Immunohistochemical staining (Fig. 3) is carried out with 5-HT2BR antibody.ApoE-/- mouse high fat diet formed atherosclerosis after 12 weeks
Model (AS), compared with the C57BL/6J mouse of normal diet, film and plaque location expression increase 5-HT2BR in the blood vessel.
After four groups of mouse different diets 12 weeks of step 1, cut using the frost of mouse aorta efferent tract patch
Piece carries out immunofluorescence dyeing, and using 5-HT2BR antibody (BD Pharmingen, 556334), (5-HT2BR antibody is by Alexa
Fluor 555dye label) 5-HT2BR is positioned, use α-SMA antibody (abcam, ab5649) (α-SMA antibody quilt
Alexa Fluor 488dye label) (marker gene that α-SMA gene is smooth muscle cell) is positioned to smooth muscle cell,
And nucleus is positioned with DAPI stain.As a result (Fig. 4) is shown, 5-HT2BR is positioned at patch smooth muscle cell.
Embodiment 2,5-HT2BR antagonist can inhibit the migration of smooth muscle cell and the formation of atherosclerotic plaque
1, the influence of 5-HT2BR and its antagonist for smooth muscle cell migration function
The trans-well experiment detection 5-HT2BR of influence using cell scratch and to(for) smooth muscle cell migration function,
Experiment is in triplicate.
Cell scratch experiment process is as follows: rat aorta smooth muscle cell is cultivated 24 hours in containing serum-free DMEM
Afterwards, cell surface is scraped with sterile sample injector suction nozzle, forms 0.5mm wide and damage cell-free region, under serum-free culturing conditions
It is thin that 5-HT, 5-HT2BR specific agonist BW723C86 or 5-HT2BR specific antagonists LY272015+5-HT processing is added
Born of the same parents take a picture in processing 0,3,6,12 and 24 hour using phase contrast microscope, and measure damage field both sides iuntercellular away from more
The speed of conjunction indicates the change of cell migration ability.Wherein BW723C86 and LY272015 is Tocris Bioscience public
Product is taken charge of, article No. is respectively 1059 and 30772；5-HT is Sigma-Aldrich Products, article No. H9523；Rat is actively
Smooth muscle cells are SD rat primary subtituted culturing cell.
As a result as shown in figure 5, the results show that 5-HT and 5-HT2BR specific agonist BW723C86 can promote smoothly
The migration of myocyte, and 5-HT2BR specific antagonists LY272015 inhibits cell migration caused by 5-HT: it is small in processing 24
When, the migration distance of smooth muscle cell is 136.6 ± 7.8 μm in control group (ctrl)；5-HT treated smooth muscle cell
Migration distance is 240.2 ± 21.3 μm；The migration distance of BW723C86 treated smooth muscle cell is 221.4 ± 12.8 μm,
Respectively 1.621 times and 0.922 times of control group and 5-HT processing；The migration distance of LY272015 treated smooth muscle cell
Be 133.7 ± 10.9 μm, respectively control group, 5-HT and BW723C86 processing 0.979 times, 0.557 times and 0.604 times.
Trans-well experimentation is as follows: rat aorta smooth muscle cell is through trypsin digestion, with containing tryptose
The DMEM of enzyme inhibitor (1mg/ml) is collected, and is incubated at (4 × 10 in the coated cell Boyden of fiber adhesion element4A cell/
Hole), after synchronization, it is added in lower room and contains PDGF-BB (10ng/ml) and different disposal (5-HT, 5-HT2BR specific agonism
Agent BW723C86 or 5-HT2BR specific antagonists LY272015+5-HT) serum-free DMEM, (PDGF-BB be smooth muscle it is thin
The chemoattractant of born of the same parents' migration), 37 DEG C are incubated for 24 hours.The small indoor surface cell in upper layer, 4% poly first of bottom cell are wiped with cotton swab
Aldehyde fixes 20 minutes, and through haematoxylin dyeing, (200 ×) take 6 visual field observations at random under inverted microscope, counts cell number.Separately
With 0.1% violet staining, cell migration quantity, i.e. migratory activity are observed.
As a result as shown in fig. 6, the results show that 5-HT and 5-HT2BR specific agonist BW723C86 can promote smoothly
The migration of myocyte, and 5-HT2BR specific antagonists LY272015 inhibits cell migration caused by 5-HT: it is small in processing 24
When, the migratory activity of smooth muscle cell is 45.00 ± 7.918 in control group (ctrl)；5-HT treated smooth muscle cell
Migratory activity is 108.0 ± 17.87；The migratory activity of BW723C86 treated smooth muscle cell is 96.80 ± 20.63, point
Not Wei control group and 5-HT processing 2.151 times and 0.896 times；The migratory activity of LY272015 treated smooth muscle cell is
52.60 ± 7.467, respectively 1.169 times, 0.487 times and 0.543 times of control group, 5-HT and BW723C86 processing.
Show that 5-HT2BR has mediated smooth muscle cell migration caused by 5-HT, and 5-HT2BR antagonist can inhibit
The migration of smooth muscle cell.
2,5-HT2BR antagonist can inhibit the formation of atherosclerotic plaque
The male ApoE-/- mouse for taking 10 8 week old, is randomly divided into two groups, respectively experimental group and control group, and every group 5
Only.Experimental group and control group are carried out the following processing, experiment is in triplicate.
Control group mice is handled in accordance with the following methods: high in fat feed being carried out to every mouse in control group respectively
It supports, nursings food is western diet (western diet, Research Diet company, D12079B), the of high fat diet
Continuous 84 days of daystart daily every mouse peritoneal injection velhicle (ethyl alcohol: propylene glycol: water [volume ratio 10:50:
40]) 50 μ l/10g weight, by first time injection when Zhou Jiwei is handled the 1st week.Before carrying out high fat diet and injection velhicle
Measure weight.
Experimental mice is handled in accordance with the following methods: high in fat feed being carried out to every mouse in control group respectively
It supports, nursings food is western diet (western diet, Research Diet company, D12079B), the of high fat diet
(antagonism agent solution was by 5-HT2BR specific antagonist for every mouse peritoneal injection antagonism agent solution daily in continuous 84 days for daystart
Agent RS127445 (Tocris Bioscience 2993) and velhicle is formed, and the concentration of RS127445 is 1mg/5ml) 50 μ
L/10g weight, by first time injection when Zhou Jiwei is handled the 1st week.
1) control group and experimental mice take the progress of its aorta on the 12nd week in processing respectively after handling accordingly respectively
Oil red O stain (A in Fig. 7), and measure the gross area (B in Fig. 7) of atherosclerotic plaque.The results show that injection
The plaque area of the experimental mice of RS127445 is less than the control group mice of injection velhicle, injects the control of velhicle
The plaque area of group mouse is 8.080 ± 0.735mm2, inject the experimental mice of RS127445 plaque area be 2.758 ±
0.456mm2, significantly less than the control group mice of injection velhicle.Show that 5-HT2BR antagonist can inhibit artery athero-
The formation of plaque.
2) control group and experimental mice take its aorta petal spot on the 12nd week in processing respectively after handling accordingly respectively
Block carries out frozen section and carries out oil red O stain (C in Fig. 7), and measures the gross area (D in Fig. 7) of aorta petal patch.As a result
It has been shown that, the aorta petal plaque area for injecting the experimental mice of RS127445 are less than the control group mice of injection velhicle,
The aorta petal plaque area for injecting the control group mice of velhicle is 0.269 ± 0.034mm2, inject the reality of RS127445
The aorta petal plaque area for testing group mouse is 0.138 ± 0.022mm2, significantly less than the control group mice of injection velhicle.
Show that 5-HT2BR antagonist can inhibit the formation of aorta petal atherosclerotic plaque.
3) in control group and experimental mice after respective handling, it is primary (A in Fig. 8) that weight is measured weekly.?
Velhicle handles the 0-7 weeks of control group mice, and control group mice weight handles the experimental group of corresponding time to RS127445
The basic indifference of mouse weight, at the 8th, 9,11 and 12 week of velhicle processing control group mice, control group mice weight was aobvious
Write and be higher than the experimental mice weight that RS127445 handles the corresponding time: velhicle is handled the 8th, 9,11 and 12 week, control group
The weight of mouse is respectively 29.7 ± 0.4g, 29.9 ± 0.4g, 29.8 ± 0.5g and 30.2 ± 0.5g；RS127445 processing the 8th,
9,11 and 12 weeks, the weight of experimental mice be respectively 28.0 ± 0.4g, 28.2 ± 0.5g, 27.9 ± 0.5g and 28.1 ±
0.5g.Show that RS127445 can reduce mouse weight.
4) in control group and experimental mice after respective handling, total cholesterol in mice plasma is measured within every three weeks respectively and is contained
Amount and total content of triglyceride (B and C, table 1 in Fig. 8).
Table 1, different disposal mice plasma in total cholesterol level and total content of triglyceride (mg/dL)
The results show that total cholesterol level was substantially less than corresponding respectively in experimental mice blood plasma in processing the 3-12 weeks
The control group mice for handling the time, in processing the 12nd week, total cholesterol level was control group mice in experimental mice blood plasma
0.78 times；Total content of triglyceride is substantially less than the respective handling time respectively in processing the 6-12 weeks, experimental mice blood plasma
Control group mice, in processing the 12nd week, total content of triglyceride was 0.61 times of control group mice in experimental mice blood plasma.
Show that RS127445 can reduce total cholesterol and total content of triglyceride in mice plasma.
5) control group and experimental mice take its aorta petal patch to carry out frost respectively and cut respectively after handling accordingly
Piece carries out immunofluorescence dyeing, is dyed using the α-SMA antibody in embodiment 1 to smooth muscle cell, and with DAPI stain
Nucleus is positioned.
The smooth muscle cell content of experimental mice aorta petal patch reduces (Fig. 9), control group mice aorta petal spot
It is 0.2441 ± 0.0224% that smooth muscle cell, which accounts for the percentage of plaque area, in block, is put down in experimental mice aorta petal patch
The percentage that sliding myocyte accounts for plaque area is 0.1061 ± 0.0227%, is 0.44 times of control mice, substantially less than compares
Group mouse.Show that RS127445 in atherosclerotic plaque forming process, affects smooth muscle shift function.
6) control group and experimental mice take the table of its aorta detection 5-HT2BR respectively after handling accordingly respectively
Up to situation.
According to the method in embodiment 1, the expression of the 5-HT2BR in aorta is detected on rna level (in Figure 10
A).The results show that the 5-HT2BR expression in control group mice aorta is significantly higher than experimental group on rna level.
According to the method in embodiment 1, the expression feelings of 5-HT2BR are detected on protein level using western-blot
Condition (B in Figure 10).The results show that the 5-HT2BR expression in control group mice aorta is higher than experiment on protein level
Group.
According to the method in embodiment 1, immunohistochemical staining is carried out (in Figure 10 with 5-HT2BR Antibody on Mouse aorta
C).The results show that the 5-HT2BR expression in control group mice aorta is higher than experimental group on protein level.
The above result shows that RS127445 can inhibit the expression of 5-HT2BR.
Claims (6)
1. reduce animal body in 5-HT2BR content substance preparation treatment and/or prevention of arterial atherosis product or by
Application in the product of atherosclerosis associated diseases；The substance of 5-HT2BR content is 5- in the reduction animal body
HT2BR specific antagonists；The 5-HT2BR specific antagonists are RS127445 or LY272015.
2. application according to claim 1, it is characterised in that: the product is drug；And/or the animal body is
Artery.
3. applying according to claim 2, it is characterised in that: the artery be aorta, aortic branch, coronary artery,
Arteria carotis, cerebral artery, the arteria renalis, mesenteric artery, pulmonary artery or artery of extremity.
4. application according to claim 1 to 3, it is characterised in that: described to be by atherosclerosis associated diseases
The disease of vascular smooth muscle cells exception or total cholesterol or total content of triglyceride caused extremely；The atherosclerosis
For the atherosclerosis of vascular smooth muscle cells exception or total cholesterol or total content of triglyceride caused extremely.
5. application according to claim 4, it is characterised in that: the vascular smooth muscle cells are the vascular smooth extremely
Migration, proliferation and/or the Phenotypic change of myocyte；And/or the total cholesterol or total content of triglyceride are total gallbladder in blood plasma
Sterol or total content of triglyceride.
6. application according to claim 1 to 3, it is characterised in that: described to be by atherosclerosis associated diseases
Coronary heart disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610049371.8A CN105561313B (en) | 2016-01-25 | 2016-01-25 | It reduces 5-HT2BR content and its active substance is inhibited to treat and prevent the application in atherosclerosis product in preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610049371.8A CN105561313B (en) | 2016-01-25 | 2016-01-25 | It reduces 5-HT2BR content and its active substance is inhibited to treat and prevent the application in atherosclerosis product in preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105561313A CN105561313A (en) | 2016-05-11 |
| CN105561313B true CN105561313B (en) | 2018-12-25 |
Family
ID=55872305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610049371.8A Active CN105561313B (en) | 2016-01-25 | 2016-01-25 | It reduces 5-HT2BR content and its active substance is inhibited to treat and prevent the application in atherosclerosis product in preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105561313B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117085130A (en) * | 2022-05-11 | 2023-11-21 | 上海交通大学医学院附属仁济医院 | Application of HTR2b activator in improving cerebral ischemia reperfusion injury |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102573993A (en) * | 2009-07-31 | 2012-07-11 | Anamar股份公司 | Compounds for treatment of inflammation |
| CN103467596A (en) * | 2012-06-06 | 2013-12-25 | 北京大学 | Novel target spot for treatment of pulmonary arterial hypertension |
-
2016
- 2016-01-25 CN CN201610049371.8A patent/CN105561313B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102573993A (en) * | 2009-07-31 | 2012-07-11 | Anamar股份公司 | Compounds for treatment of inflammation |
| CN103467596A (en) * | 2012-06-06 | 2013-12-25 | 北京大学 | Novel target spot for treatment of pulmonary arterial hypertension |
Non-Patent Citations (2)
| Title |
|---|
| 5-羟色胺2受体拮抗剂对血管***的作用研究进展;温绍君等;《中华内科杂志》;20040430;第43卷(第4期);第314-315页 * |
| Identification of a Key Amino Acid of the Human 5-HT2B Serotonin Receptor Important for Sarpogrelate Binding;Habib Abul Muntasir等;《J Pharmcol Sci》;20070703;第274-277页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105561313A (en) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ben-Shlomo et al. | Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase | |
| Zaha et al. | AMP-activated protein kinase regulation and biological actions in the heart | |
| Ceylan-Isik et al. | Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction | |
| Sui et al. | Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex | |
| Jensen-Urstad et al. | Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger? | |
| US9682121B2 (en) | Application of irisin in myocardial ischemia reperfusion | |
| Naska et al. | An Essential Role for the Integrin-Linked Kinase–Glycogen Synthase Kinase-3β Pathway during Dendrite Initiation and Growth | |
| Tsai et al. | Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes | |
| Wu et al. | Aucubin protects against pressure overload‐induced cardiac remodelling via the β3‐adrenoceptor–neuronal NOS cascades | |
| US20120232142A1 (en) | Novel use of dimethylfumarate | |
| CN105535001A (en) | Application of salidroside to preparation of medicine for treating diabetic foot | |
| Hua et al. | Metformin increases cardiac rupture after myocardial infarction via the AMPK-MTOR/PGC-1α signaling pathway in rats with acute myocardial infarction | |
| CN105561313B (en) | It reduces 5-HT2BR content and its active substance is inhibited to treat and prevent the application in atherosclerosis product in preparation | |
| Jia et al. | Different roles of BAG3 in cardiac physiological hypertrophy and pathological remodeling | |
| TW202023541A (en) | Application of chiglitazar and its related compounds | |
| CN109689083B (en) | Anti-angiogenic pharmaceutical composition containing cyclopentadepsipeptide as active ingredient | |
| Zhou et al. | MnTBAP stimulates angiogenic functions in endothelial cells through mitofusin-1 | |
| CN109771411A (en) | Dihydroquercetin is used to prepare the purposes in the drug for the treatment of fatty liver | |
| Blask et al. | Newinsights into Melatonin Regulation of Cancer Growth | |
| CN107929323A (en) | Treat preparation method of Tissue of Diabetic Wound injection and products thereof | |
| Bazekin et al. | Morphofunctional Assessment of the Glycyrrhizinic Acid Effect on Myocardium of Rats under Adrenaline Loading. | |
| US20100168219A1 (en) | Chronic inflammation and transplantation | |
| CN103037901A (en) | Cd36 inhibition to control obesity and insulin sensitivity | |
| EA039485B1 (en) | Use of 4-hydroxytestosterone as angiogenesis inhibitor | |
| Marin-Spiotta et al. | A single episode of central glucoprivation reduces the adrenomedullary response to subsequent hypoglycemia in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |